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Transposon linker insertion mutagenesis of a full-length infectious clone (IC) (pBIC) of the pathogenic classical swine fever virus (CSFV)
strain Brescia was used to identify genetic determinants of CSFV virulence and host range. Here, we characterize a virus mutant, RB-C22v,
possessing a 19-residue insertion at the carboxyl terminus of E1 glycoprotein. Although RB-C22v exhibited normal growth characteristics in
primary porcine macrophage cell cultures, the major target cell of CSFV in vivo, it was markedly attenuated in swine. All RB-C22v-infected pigs
survived infection remaining clinically normal in contrast to the 100% mortality observed for BICv-infected animals. Comparative pathogenesis
studies demonstrated a delay in RB-C22v spread to, and decreased replication in the tonsils, a 102 to 107 log10 reduction in virus titers in lymphoid
tissues and blood, and an overall delay in generalization of infection relative to BICv. Notably, RB-C22v-infected animals were protected from
clinical disease when challenged with pathogenic BICv at 3, 5, 7, and 21 days post-RB-C22v inoculation. Viremia, viral replication in tissues, and
oronasal shedding were reduced in animals challenged at 7 and 21 DPI. Notably BICv-specific RNA was not detected in tonsils of challenged
animals. These results indicate that a carboxyl-terminal domain of E1 glycoprotein affects virulence of CSFV in swine, and they demonstrate that
mutation of this domain provides the basis for a rationally designed and efficacious live-attenuated CSF vaccine.
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Classical swine fever virus (CSFV) is the causative agent of
classical swine fever (CSF), a highly contagious and significant
pathogen of swine (van Oirschot, 1986). CSFV, a member of the
genus Pestivirus of the family Flaviviridae (Wengler et al.,
1995), is a small enveloped virus with a single-stranded, 12.5 kb
RNA genome of positive polarity that is translated as a single
polyprotein (Rice, 1996). The approximately 4000 amino acid
polyprotein, once processed, gives rise to the following 11 to 12
final cleavage products: NH2-Npro-C-E
rns-E1-E2-p7-NS2-
NS3-NS4A-NS4B-NS5A-NS5B-COOH (Rice, 1996). Protein
C and glycoproteins Erns, E1, and E2 represent structural
components of the virion (Thiel et al., 1991). While E1 and E2
are anchored to the envelope by their carboxyl termini, Erns
appears to be covalently associated with the other envelope
glycoproteins (Weiland et al., 1990, 1999). Erns and E2 are
present as disulfide-linked homodimers on the virion surface,5) 116 – 127
www.e
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1990). Although Erns and E2 have been shown to function in
viral pathogenesis, virus attachment to target cell, and the
induction of a protective immune responses (Hulst et al., 1993,
1998; Hulst and Moormann, 1997; Meyers et al., 1999; Risatti
et al., 2005; Ruggli et al., 1996; van Gennip et al., 2000, 2004;
van Zijl et al., 1991; Weiland et al., 1990, Widjojoatmodjo et al.,
2000), the function of E1 is less well understood. A recent study
has shown that E1 and E2 are sufficient to mediate entry of
pseudotyped retrovirus into swine cells (Wang et al., 2004).
Although highly virulent strains of CSFV in pigs cause
severe disease characterized by high morbidity and mortality,
strains of moderate to low virulence that induce prolonged
chronic disease have been isolated (van Oirschot, 1986). In
addition, avirulent strains of CSFV obtained through cell
culture passage have provided the basis for effective live-
attenuated vaccines (LAV) for CSF, exhibiting the ability to
infect animals and induce protective immunity without
inducing clinical disease (Terpstra et al., 1990). Specific
genetic determinants are likely responsible for these different
phenotypes; however, the genetic basis of CSFV virulence
remains poorly understood (Aynaud, 1988; Biront et al., 1987).
Notably, recent development of cDNA infectious clones (IC) of
attenuated and virulent CSFV strains is enhancing understand-
ing of molecular mechanisms of viral replication and patho-
genesis and allowing rational design and engineering of
improved LAV for CSF (Mayer et al., 2004; Meyers et al.,
1999; Moormann et al., 1996; Moser et al., 2001; Risatti et al.,
2005; Ruggli et al., 1996; van Gennip et al., 2000, 2004;
Widjojoatmodjo et al., 2000).
Using CSFV IC, several viral proteins as having roles in
viral virulence, including Erns, Npro, and E2, have beenFig. 1. RB-C22 virus was generated by transposon linker insertion mutagenesis of a
virus (CSFV) strain Brescia (A). A 57-nucleotide in-frame insertion encoding 19
glycoprotein E1, four residues upstream (dotted line) of the cleavage site between E1
position, numbers in bold italics indicate amino acid residue position. Underlined r
glycoproteins E1 and E2 expression in infected SK6 cells was done by Western imm
BICv, or mock-infected (control) and harvested at 48 h post-infection. Cell lysates
detected with an E1 specific rabbit antiserum, and CSFV E2 (C) was detected withidentified. Depending on the specific Erns mutations engineered
into virulent CSFV strain Alfort/187, variable degrees of
attenuation were observed when mutants were inoculated in
swine (Meyers et al., 1999). Complete deletion of Npro from
Alfort/187 and Eystrup strains abrogates their virulence for
swine (Mayer et al., 2004). Recently, CSFV IC have been used
to demonstrate that E2 harbors genetic determinants of
virulence (Risatti et al., 2005; van Gennip et al., 2004).
In efforts to identify additional virulence and host range
determinants of CSFV, we used transposon linker insertion
mutagenesis (TLIM) (Hallet et al., 1997; Hobom et al., 2000)
to mutate an IC of the pathogenic strain Brescia (pBIC) (Risatti
et al., 2005). A viral mutant, RB-C22v, with a 57 nucleotide
insertion at genomic position 2429 was obtained and found to
be highly attenuated in pigs. RB-C22v exhibited decreased
replication in tonsils, limited generalization of infection, and a
significant reduction of virus shedding following infection of
swine. Notably, RB-C22v-infected pigs challenged with
pathogenic BICv at 3, 5, 7, and 21 days post-RB-C22v
inoculation (DPI) were protected from clinical disease. These
data indicate that mutation of a carboxyl-terminal domain of
the E1 glycoprotein markedly affects swine virulence. Identi-
fication of this and other CSFV virulence and host range
determinants will permit the rational design of CSF LAV with
improved safety, efficacy, and utility.
Results
Generation of attenuated BICv mutant virus RB-C22v
Mutants of BICv were obtained using transposon linker
insertion mutagenesis, and derivative viruses were rescuedfull-length infectious clone (IC) (pBIC) of the pathogenic classical swine fever
amino acids (box) is located at the carboxyl terminus of RB-C22v envelope
and envelope glycoprotein E2 (solid line). Numbers in bold indicate nucleotide
esidues in bold italics represent the NotI restriction site. The analysis of CSFV
unoblot (B and C). SK6 monolayers were infected (MOI = 1) with RB-C22v,
were run under denaturing conditions in 12% SDS-PAGE. CSFV E1 (B) was
mAb WH303.
Fig. 2. (A) Multistep growth curve of BICv and RB-C22v on swine
macrophage cell cultures. Primary swine macrophage cell cultures were
infected (MOI of 0.1) with CSFV BICv (open squares) or RB-C22v (filled
squares). At times post-infection, samples were collected and titrated for virus
yield. Data are means and standard errors of three independent experiments. (B)
Plaque formation of CSFV BICv and RB-C22v on SK6 cell cultures. Cell
cultures were infected with approximately 75 TCID50 of CSFV BICv or RB-
C22v, overlaid with 0.5% agarose, incubated at 37 -C for 3 days, fixed with
50% (v/v) ethanol/acetone, and stained by immunohistochemistry as described
in Materials and methods.
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transfection. One viral mutant, RB-C22v, exhibited an altered
virulence phenotype in swine (data not shown). RB-C22v
contained at genomic position 2429, a 57-nucleotide in-frame
insertion encoding 19 amino acids inserted at the carboxyl
terminus of envelope glycoprotein E1, four residues upstream
of the cleavage site between E1 and envelope glycoprotein E2
(Fig. 1A). The complete nucleotide sequence of RB-C22v was
obtained and compared with that of BICv. Complete nucleotide
sequences for both viruses were identical except for the 57-
nucleotide insertion in RB-C22v (data not shown). Relative
electrophoretic mobility in Western blot did not show
noticeable differences between E1 or E2 in RB-C22v-infected
and BICv-infected SK6 cells (Figs. 1B and C).Table 1
Swine survival and fever response following infection with RB-C22v or BICv
Virus Number of
survivors/total
Mean time to death;
days (SD)
Mean time of fe
days (SD)
RB-C22v 8/8 – 5.5 (1.0)
BICv 0/5 9.12 (3.09) 4.4 (0.8)
SD: standard deviation.Mutation of E1 does not affect growth of RB-C22v in porcine
macrophage cell cultures
Growth characteristics of RB-C22v and BICv were com-
pared in a multistep growth curve by infecting primary swine
macrophage cell cultures (MOI = 0.1) and determining titers
for both at times post-infection. Growth kinetics of RB-C22v
and BICv were indistinguishable (Fig. 2A). Notably, the plaque
size of RB-C22v on SK6 cell cultures was reduced by more
than 50% relative to plaques formed by BICv (Fig. 2B).
E1 mutation affects CSFV virulence in pigs
To examine the effect of the RB-C22v E1 mutation on pig
virulence, pigs were inoculated IN with 105 TCID50 of RB-
C22v or BICv, and the disease course was monitored. The
disease pattern observed for RB-C22v-infected animals
contrasted markedly with that seen in BICv-infected animals.
All RB-C22v-infected animals survived and remained clini-
cally normal following infection (with the exception of a
transient hyperthermia in half of the infected animals),
whereas animals infected with BICv exhibited 100% mortality
and presented clinical signs of CSF 3 to 7 DPI, with
symptoms progressing until death (Table 1). Blood lympho-
cyte and platelet counts dropped drastically in BICv-infected
animals at 4 to 6 DPI and remained low until death, while a
transient and much less dramatic effect was observed in the
RB-C22v-infected animals (Fig. 3). Both mean and maximum
viremia titers in RB-C22v-infected animals were significantly
reduced (102 to 107 log10) relative to those in control animals
during the acute disease period (Table 2). Additionally, RB-
C22v titers in nasal swabs and tonsil scrapings were
significantly decreased (101 to 103 log10) (Table 2). The
complete nucleotide sequence of RB-C22v, isolated at 6 DPI
from the tonsils of an infected pig, was identical to RB-C22v
stock virus used for animal inoculations (data not shown).
These results demonstrate that RB-C22v is markedly attenu-
ated for swine.
For detailed comparison of RB-C22v and BICv pathogen-
esis, randomly selected animals were euthanized at 2, 4, 6, 9,
11, and 16 DPI, and tissue samples were collected for virus
titration, histopathological, and immunohistochemical analysis.
Virus titers in tissues are shown in Table 2. RB-C22v
replication in tonsils was significantly decreased (between
102 and 107 log10, depending on DPI) relative to BICv. At 4–6
DPI, RB-C22v was present in the draining submandibular
lymph node but at titers 100- to 1000-fold lower than those
observed in BICv-infected animals. Generalization of infection
occurred in both RB-C22v and BICv-infected animals by 4ver onset; Mean time duration of fever;
days (SD)
Max daily temperature;
average (SD)
0.7 (0.8) 104.1 (0.6)
4.6 (0.8) 106.1 (0.5)
Fig. 3. Cell counts of (A) peripheral blood lymphocytes and (B) platelets in
pigs infected with BICv (empty squares) or RB-C22v (filled squares). Each
point represents the mean and standard error of 3 or more animals.
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kidney, and mesenteric lymph node were significantly lower
(approximately 102 to 103 log10) than values observed for
BICv-infected animals. Interestingly, central nervous system
(CNS) involvement in RB-C22v-infected animals was mark-Table 2
Virus titers in clinical samples and tissues following infection with BICv or RB-C2
Samples BICv (log10 TCID50/ml) DPI
2 4 6 9 11
Nasal swabs Neg Neg 2.30 (1.15) 4.47 (1.15) ND
Tonsil scrapings Neg 2.79 (0.26) 2.00 (0.08) 4.47 (0.19) ND
Blood Neg 3.11 (0.34) 6.50 (0.27) 9.02 (0.28) ND
Tonsil 1.40 (1.40) 5.55 (0.75) 6.80 (0.17) 7.71 (0.09) 7.80 (0.00)
Mandibular
lymph node
Neg 4.05 (0.08) 5.55 (0.25) 7.47 (0.34) 7.80 (0.00)
Mesenteric
lymph node
Neg 2.14 (0.47) 5.64 (0.17) 7.55 (0.25) 7.80 (0.00)
Spleen Neg 2.14 (1.17) 5.97 (0.00) 7.47 (0.34) 7.80 (0.00)
Kidney 2.47 (0.67) 1.97 (0.00) 4.47 (0.17) 7.22 (0.42) 7.47 (0.00)
Bone marrow Neg 3.05 (0.08) 7.63 (0.00) 7.87 (0.07) 6.99 (0.00)
Brain Neg Neg 5.05 (1.08) 4.64 (0.84) 6.80 (0.00)
a Titers expressed as TCID50/ml. DPI, days post-infection. ND, not determined. Nedly reduced relative to that seen in BICv-infected animals
(Table 2). Overall, RB-C22v infection resulted in reduced
generalization of infection and significantly lower virus titers in
tissues.
Histological lesions in pigs inoculated with BICv were
observed as early as 4 DPI. These included tonsilar and
submandibular lymphoid necrosis and depletion, which pro-
gressed to abscess formation by 10 DPI. Additionally, between
6 and 10 DPI, there was moderate to marked histiocytic
hyperplasia and reticuloendothelial cell proliferation (Fig. 4).
RB-C22v-infected pigs showed similar pathology of the tonsil
and regional submandibular lymph node, but the degree was
markedly reduced, with a minimal to mild lymphoid necrosis
and only a mild histiocytosis. Notably, lesions in RB-C22v-
infected animals began to resolve with evidence of lymphoid
hyperplasia by 11 DPI. BICv-infected spleen was characterized
by moderate to severe lymphoid follicular depletion, necrosis,
and mild to moderate histiocytosis, while, in RB-C22v-infected
pigs, there were negligible changes in the spleen with minimal
lympholysis and depletion (Fig. 4). As early as 6 DPI, BICv-
infected pigs had a moderate to marked meningoencephalitis
with vasculitis and prominent perivascular lymphohistiocytic
cuffs, and, by 10 DPI, cerebral and cerebellar necrosis were
associated with severe vasculitis and thrombosis. In contrast,
there was minimal pathology in CNS of the RB-C22v-infected
pigs, with only 7 of 18 animals exhibiting rare perivascular
cuffs of a few lymphocytes and macrophages and foci of
gliosis.
The presence of CSFV antigen in tissues of infected
animals was consistent with the degree and distribution of
lesions and virus tissue titers. In BICv-infected pigs, there
was antigen in superficial and cryptic tonsilar epithelial cells
and tonsilar endothelium by 2 DPI and in tonsilar macro-
phages and lymphoid follicles with moderate to marked
immunoreactivity by 4 DPI (Fig. 4). Similar immunoreac-
tivity was observed in mandibular lymph node and the
spleen, which included macrophages and endothelium. In the
brain of the BICv-infected animals, there was CSFV antigen
labeling by 2 DPI with moderate to marked immunoreac-2va
RB-C22v (log10 TCID50/ml) DPI
16 2 4 6 9 11 16
ND Neg Neg 1.85 (0.19) 1.84 (0.29) Neg Neg
ND Neg 1.92 (0.03) Neg Neg Neg Neg
ND Neg 2.09 (0.32) 2.81 (0.75) 1.84 (0.08) Neg Neg
ND Neg 3.19 (0.53) 5.58 (0.23) 1.97 (0.17) 1.76 (0.39) 1.89 (0.12)
ND Neg 1.86 (0.10) 2.58 (0.92) Neg Neg Neg
ND Neg 2.14 (0.16) 2.58 (0.24) Neg Neg Neg
ND Neg Neg 1.97 (0.00) 1.86 (0.10) Neg Neg
ND Neg Neg Neg Neg Neg Neg
1.80 Neg 1.97 (0.17) 3.08 (0.78) 1.97 (0.17) Neg Neg
1.80 Neg Neg Neg Neg Neg Neg
umbers in parenthesis indicate standard deviation. Neg: 1.80 TCID50/ml.
Fig. 4. Detection of CSFVantigens in lymphoid organs of pigs infected with BICv or RB-C22v viruses by immunohistochemistry. Tonsils at 9 DPI (A and B) and 11
DPI (C and D) in animals infected with RB-C22v (A and C) or BICv (B and D). Note hyperplastic lymphoid follicles (*) and abundant immunoreactivity in the crypt
epithelium (D), but not in lymphoid follicles, in RB-C22v-infected animals versus abundant immunoreactivity both in lymphoid follicles and crypt epithelium, along
with depletion of the lymphoid follicles, in animals infected with BICv. Also note at 11 DPI the hyperplasic periarteriolar lymphoid sheaths (E) (Y) and absence of
immunoreactivity in the spleen of RB-C22v-infected animals (E) versus depleted lymphoid follicles and abundant immunoreactivity in the periarteriolar area of
BICv-infected animals (F).
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macrophages, and in glial cells, with the latter more
pronounced at 10 DPI. In contrast, the highest immuno-Table 3
Swine survival and fever response of RB-C22v-infected animals following challen
Challenge
DPIa
Number of
Survivors/total
Mean time to death;
days (SD)b
Mean time of f
days (SD)
1 1/3 12.6 (3.5) 4.0 (0.0)
3 3/3 – 4.0c
5 3/3 – 3.0c
7 8/8 – None
21 8/8 – None
Controld 0/8 9.0 (2.8) 3.6 (1.7)
a Days post-infection with RB-C22v.
b SD, standard deviation.
c Observed on a single animal.
d Control, no RB-C22v infection.reactivity in RB-C22v-infected pigs was observed in tonsils,
with a significant reduction of staining in the submandibular
lymph node, spleen, and brain. In the brain, minimalge with BICv
ever onset; Mean time duration of fever;
days (SD)
Max daily temperature;
average (SD)
7.0 (4.3) 106.8 (0.3)
1.0 104.5 (0.7)
1.0 104.1 (0.6)
– 103.7 (0.3)
– 102.4 (0.3)
4.4 (1.3) 106.1 (0.5)
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animals.
Overall, the data indicate that mutation of glycoprotein E1
affects CSFV virulence for swine. RB-C22v infection is
characterized by an absence of clinical disease, decreased viral
replication in tonsils, limited generalization of infection, and
dramatically reduced virus shedding.Fig. 5. (A) Peripheral white blood cell, (B) lymphocyte, and (C) platelet counts in pi
or 5 DPI (diamonds) with BICv. Counts are expressed as numbers/ml and represent t
I, infection with RB-C22v. C, challenge with BICv.RB-C22v infection protects pigs against challenge with
pathogenic BICv
The ability of RB-C22v to induce protection against BICv
challenge was evaluated. At 1, 3, 5, 7, and 21 DPI with RB-
C22v, pigs were challenged with 105 TCID50 of pathogenic
BICv.gs infected with RB-C22v and challenged at 1 DPI (triangles), 3 DPI (squares),
he mean of all individuals in the group, with error bars indicating standard error.
Table 4
Virus titers and RT-PCR detection of viral RNA in clinical samples obtained from RB-C22v-infected and uninfected control animals challenged with BICv at 7 DPI
Days post-challenge RB-C22v-infected (n = 8) Non-infected (n = 4)
Tonsil scrapings Nasal Swabs Viremia Tonsil scrapings Nasal Swabs Viremia
Titera RNAb Titer RNA Titer Titer RNA Titer RNA Titer
5 Neg  Neg  Neg 2.4 (1.6) + 3.1 (0.2) + 5.6 (0.8)
7 Neg  Neg  Neg 5.4 (0.8) + 4.8 (0.0) + 7.5 (0.7)
9 Neg  Neg  Neg 4.6 (0.8) Dc 6.0 (0.0) + NDd
12 Neg  Neg  Neg D D D D D
16 Neg  Neg  Neg D D D D D
19 Neg  Neg  Neg D D D D D
Neg: 1.80 TCID50/ml.
a Virus titers expressed as log10 TCID50/ml and standard deviation shown in parenthesis. , negative.
b CSFV viral RNA present (+) or absent () as detected by real-time RT-PCR (23).
c D, dead animals.
d ND, not determined.
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were partially protected. Animals developed hematological
changes and clinical signs, including leukopenia, lymphocyto-
penia, and thrombocytopenia by 3 days post-challenge (DPC)
with fever, anorexia, and depression evident by 5 DPC (Table 3
and Fig. 5). Of these three animals, two pigs died (9 and 13
DPC). Clinical signs and body temperature of the surviving
animal returned to normal by 12 DPC (Table 3). Control pigs
receiving only BICv challenge developed anorexia, depression,
and fever by 4 DPC, a marked reduction of leukocytes,
lymphocytes, and platelets by day 5 DPC, and died or were
euthanized in extremis by 12 DPC (Table 3).
Notably, complete protection against BICv-induced clinical
disease was induced 3 days post-RB-C22v infection. All pigs
survived infection and remained clinically normal, with only a
single animal presenting a transient fever at 4 DPC (Table 3). A
transient drop in hematological values was observed between 1
and 5 DPC (Fig. 5). Similarly, pigs challenged at 5, 7, and 21
days post-RB-C22v infection remained clinically normal, with
the exception of a transient fever in 2 of 19 animals (Table 3,
Fig. 5, and data not shown).
Virus was not detected in blood or oronasal swabs
samples of RB-C22v-infected pigs challenged at 7 or 21
DPI nor could viral RNA be detected in nasal and tonsil
samples by RT-PCR (Table 4 and data not shown). ViremiaTable 5
Detection of CSFV RB-C22v and BICv in tissues of swine challenged with BICv
Hours post-BICv
challenge
Pig # Tonsil
Days post-RB-C22v infection
1 3
6 1 – –
2 – RB-C22v
12 1 – RB-C22v
2 – RB-C22v
24 1 – RB-C22v
2 – RB-C22v
48 1 – RB-C22v
2 RB-C22v/BICv RB-C22v
72 1 RB-C22v/BICv RB-C22v
2 RB-C22v/BICv RB-C22vwas observed in control animals by 5 DPC, with virus titers
remaining high (107 TCID50/ml by 7 DPC) until death (Table
4). In addition, virus was titrated from oronasal swabs of
control animals by 5 DPC (Table 4), reaching titers of 106
TCID50/ml by 9 DPC.
Antibody responses to CSFV were measured by ELISA and
serum neutralization. All RB-C22v-infected animals developed
E2-specific antibodies by 14 DPI and significantly higher
levels by the time of challenge at 21 DPI as detected with both
CSFV E2-specific ELISA tests. Neutralizing antibodies were
detected in 7 of 8 RB-C22v-infected pigs as early as 14 DPI
(log10 2.02, SD = 0.12) and in serum from all animals when
challenged at 21 DPI (log10 = 2.44, SD = 0.14). Notably, RB-
C22v-infected animals at 7 DPI were efficiently protected from
BICv challenge despite lacking detectable antibodies against
CSFV at challenge (Table 3).
An RT-PCR assay that differentiates RB-C22v from BICv
was used to identify virus present in tonsils of animals
challenged at 1 or 3 DPI with RB-C22v (see Materials and
methods). Genomic RNA from both viruses was detected in
equivalent amounts in tonsils of animals challenged at 1 DPI
(Table 5). Animals in this group developed disease and were
not protected (Table 3). However, RB-C22v was the only virus
detected in tonsils of protected animals challenged at 3 DPI
(Tables 3 and 5). These data suggest that sufficient RB-C22vat 1 and 3 days following RB-C22v infection
Mandibular lymph node Spleen
Days post-RB-C22v infection Days post-RB-C22v infection
1 3 1 3
– RB-C22v – –
– RB-C22v – –
– RB-C22v – –
– RB-C22v – –
– RB-C22v – RB-C22v
– RB-C22v – RB-C22v
RB-C22v/BICv RB-C22v – RB-C22v
RB-C22v/BICv RB-C22v – RB-C22v
RB-C22v/BICv RB-C22v RB-C22v/BICv RB-C22v
RB-C22v/BICv RB-C22v RB-C22v/BICv RB-C22v
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replication.
Discussion
Here, we have shown that insertion of a 19 amino acid
peptide at the carboxyl terminus of E1 glycoprotein of the
CSFV strain Brescia resulted in in vivo attenuation. Unlike
the acute fatal disease induced by Brescia and BICv, RB-
C22v infection was sub-clinical, characterized by decreased
viral replication in tonsils, limited generalization of infection,
and reduced virus shedding. Notably, the attenuation observed
for RB-C22v was independent of its ability to replicate in
primary swine macrophage cell cultures since RB-C22v and
BICv exhibited comparable growth characteristics in these
cells (Fig. 2A).
The genetic basis and the molecular mechanisms underlying
pestivirus virulence remain largely unknown. In CSFV, recent
reports have linked specific viral proteins and genomic regions
with virulence in pigs (Hulst et al., 2001; Mayer et al., 2004;
Meyers et al., 1999; Risatti et al., 2005; van Gennip et al.,
2004). A single or double codon mutation abrogating Erns
RNAse activity of the CSFV strain Alfort attenuated the virus
for pigs (Meyers et al., 1999), as did mutation of the same
domain of Erns in BVDV (Hulst et al., 2001). Npro deletion
mutants of virulent CSFV strains Alfort/187 and Eystrup were
attenuated for pigs (Mayer et al., 2004). More recently, it has
been shown that E2 glycoprotein contains genetic determinants
for virulence (Risatti et al., 2005; van Gennip et al., 2004). This
report describes a novel CSFV virulence determinant associ-
ated with the E1 glycoprotein.
While the precise mechanism mediating RB-C22v attenu-
ation in pigs is unclear, it conceivably could involve some
aspect of virus attachment and/or entry into critical target cells.
Erns, E1 and E2 are structural glycoproteins in the CSFV virion
envelope (Weiland et al., 1990, 1999), with E1 and E2 likely
anchored to the envelope as both homo and heterodimers
linked by disulfide bridges (Thiel et al., 1991; Weiland et al.,
1990, 1999) and Erns associated with the virion but lacking the
membrane anchor (Weiland et al., 1999). Erns and E2 are
known to be involved in virus reception (Hulst and Moormann,
1997), and, more recently, E1 has also been implicated in virus
binding and entry (Wang et al., 2004). In silico analysis here
predicts that the 19 amino acid insertion at the carboxyl
terminus of RB-C22v E1 introduces an alpha helix and turns
close to the E1/E2 cleavage site. Such alteration of E1
secondary structure may directly impact a specific virulence
determinant directly on E1 or, alternatively, it may affect
virulence by altering the ability of E1 to interact with E2 or
other viral proteins critical for virus reception, cell tropism, or
viral dissemination in the host. The functional significance of
E1/E2 heterodimers for reception and infection of target cells in
vivo is not known.
Consistent with a possible direct or indirect effect for the
altered E1 on virus attachment and/or spread, RB-C22v
exhibited a small-plaque phenotype in SK6 cells when
compared with parental BICv. Hulst et al. (2000, 2001) havedescribed heparin-sulfate-binding-dependent small plaque var-
iants of CSFV Brescia that contain mutations in Erns following
serial passage in SK6 cells. Notably, these CSFV variants had
unaltered virulence phenotypes in pigs (Hulst et al., 2000,
2001). With the flaviviruses Japanese Encephalitis Virus (JEV)
and Murray Valley Encephalitis Virus (MVEV), passage in cell
culture yielded variants with a small plaque phenotype,
increased heparin affinity/sensitivity, decreased neuroviru-
lence, and inability to exit peripheral footpad inoculation sites
in a mouse model (Lee and Lobigs, 2002). The attenuated
flavivirus phenotype was conferred by mutations in the E
glycoprotein, analog of the pestivirus E2 glycoprotein (Hurrel-
brink and McMinn, 2001). It has been suggested that this
flaviviral attenuation may result from increased affinity for
glycosaminoglycans, conceivably causing variant viruses to
bind cell surface and extracellular matrix proteoglycans to an
extent that prevents viremia and spread of the virus to the brain
(Lee and Lobigs, 2002); however, attenuated mutants of
MVEV demonstrated normal binding and penetration rates,
indicating a role for the E protein in virulence at a time
subsequent to entry into the host cell (Hurrelbrink and
McMinn, 2001). The significance of these observations in
flaviviruses for CSFV RB-C22v attenuation remains to be
determined.
RB-C22v replication in vivo was limited, including reduced
viremia, generalization of infection, and viral shedding, yet, it
induced rapid protection from lethal challenge (Tables 2 and 4,
Fig. 4) similar to infectivity/protection patterns previously
described for other LAV strains of CSFV (Biront et al., 1987;
Terpstra and Wensvoort, 1988). Animals exposed to RB-C22v
and challenged with BICv at 3 and 7 DPI were protected
against clinical disease, and this was clearly before develop-
ment of detectable anti-CSFV serum antibodies at 14 DPI. The
rapid, solid, and assumedly antibody-independent protection
induced by RB-C22v likely involves innate immune mechan-
isms, e.g. macrophages/monocytes, dendritic cells, and NK
cells and their products. Data here indicates that viral
interference may also be involved in protection as only RB-
C22v was detected in tonsils of pigs protected against
challenge with BICv 3 DPI. This lack of BICv in tonsils
post-challenge is notable given that primary replication of
CSFV normally occurs in tonsils shortly after oronasal
inoculation (Biront and Leunen, 1988; van Oirschot, 1986)
(Tables 2, 3 and 5). Consistent with these observations,
absence of challenge virus in tonsils of LAV-vaccinated,
seronegative pigs challenged with a pathogenic CSFV strain
has been shown previously (Biront and Leunen, 1988).
Conversely, comparable amounts of both RB-C22v and BICv
were present in tonsils of unprotected pigs challenged 1 DPI
(Table 5). Interference with BICv colonization of, or replica-
tion in tonsils, could conceivably result from primary
replication of RB-C22v, which might induce an antiviral state
in tonsils between 1 and 3 DPI that would preclude replication
of the virulent challenge virus and progression of the disease
(Table 5).
In summary, this study has identified a virulence determi-
nant associated with the E1 glycoprotein of CSFV. This
G.R. Risatti et al. / Virology 343 (2005) 116–127124improved understanding of the genetic basis of CSFV
virulence and host range will permit rational design of live
attenuated CSF vaccines of enhanced safety, efficacy, and
utility.
Materials and methods
Cells and viruses
The SK6 swine kidney cell line (Terpstra et al., 1990) free
of Bovine Viral Diarrhea Virus (BVDV) was used throughout
this study. SK6 cells were cultured in Dulbecco’s minimal
essential medium (DMEM) (Gibco, Grand Island, NY) with
10% fetal calf serum (FCS) (Atlas Biologicals, Fort Collins,
CO). Pathogenic CSFV strain Brescia (obtained from Plum
Island Animal Disease Center, Animal and Plant Health
Inspection Service, USDA) was propagated in SK6 cells and
used for the construction of a cDNA infectious clone (pBIC)
from which infectious virus (BICv) was rescued (Risatti et al.,
2005). RB-C22v is the E1 mutant virus obtained in this study
as described below.
Production of CSFV mutant viruses
Mutants of BICv containing single 57 nucleotide linker
inserts were generated using pBIC and a transposon (Tn)
mutagenesis kit (Epicentre Technologies, Madison, WI)
according to manufacturer’s instructions. Briefly, mutant
clones containing a Tn insertion were selected in the
presence of kanamycin and sequenced using Tn-specific
primers to locate genomic position of the insert. The 1.4 kb
Tn insertion cassette was removed using NotI endonuclease,
and linearized clones were religated using T4 DNA ligase
(New England Biolabs, Beverly, MA) and transformed into
TOP 10 E. coli (Invitrogen, Carlsbad, CA). Transformants
that grew in the presence of ampicillin but not in the
presence of kanamycin were further selected, and the IC
plasmids were sequenced with CSFV Brescia specific
primers to confirm the position of the remaining 57 nt
insert. IC plasmids bearing an insert at desired positions were
used to rescue mutant viruses.
Rescue of parental and mutant viruses
Full-length pBIC and mutant IC were linearized with SrfI
and in vitro transcribed using the T7 Megascript system
(Ambion, Austin, TX). Resulting RNA was precipitated
with LiCl and transfected into SK6 cells by electroporation
at 500 V, 720 V, and 100 W with a BTX 630
electroporator (BTX, San Diego, CA). Cells were plated
in 12-well plates and 25 cm2 flasks and incubated for 4
days at 37 -C 5% CO2 atmosphere. Virus was detected by
immunoperoxidase staining using a CSFV E2 specific
monoclonal antibody (mAB) WH303 (Edwards et al.,
1991). Stocks of rescued viruses were stored at 70 -C.
Insert location was confirmed by RT-PCR followed by
sequence analysis.DNA sequencing and analysis
Full-length mutant IC and in vitro rescued mutant
viruses were completely sequenced with CSFV specific
primers by the dideoxynucleotide chain-termination method
(Sanger et al., 1977). Sequencing reactions were prepared
with the BigDye Terminator Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA). Reaction products were
sequenced on a PRISM 3730xl automated DNA Sequencer
(Applied Biosystems). Sequence data were assembled with
the Phrap software program (http://www.phrap.org), with
confirmatory assemblies performed using CAP3 (Huang and
Madan, 1999). Protein composition and structure predictions
were made using the Genetics Computer Group (GCG)
Wisconsin Package versions 7 and 10 software (Devereux
et al., 1984).
Western blot analysis
The expression of E1 and E2 in lysates of SK6 cells
infected with RB-C22v or BICv was analyzed by Western
immunoblots. CSFV E1 was detected with a rabbit antiserum
raised against the Brescia strain E1 expressed in a
Baculovirus System (BD Biosciences Clontech, Palo Alto,
CA). CSFV E2 was detected with mAb WH303. SK6
monolayers were infected (MOI = 1) with RB-C22v or
BICv, harvested at 48 h post-inoculation (HPI) using the
NuPAGE LDS sample buffer system (Invitrogen), and
incubated at 80 -C for 20 min. Samples were run under
denaturing conditions in pre-cast NuPAGE 12% Bis–Tris
acrylamide gels (Invitrogen). Western immunoblots were
performed using WesternBreeze Chemoluminescent Immuno-
detection System (Invitrogen).
Animal studies
For all animal studies, commercial pigs of 10 to 12 weeks of
age and approximately 40 lb in weight were used. To assess
virulence, pigs (n = 2) were inoculated intranasally (IN) with
105 TCID50 with mutant viruses of interest.
For pathogenesis studies, pigs (n = 45) were randomly
allocated into three groups and inoculated with BICv (group 1,
n = 17), RB-C22v (group 2, n = 26), or mock-infected (group
3, n = 2). Clinical signs (anorexia, depression, purple skin
discoloration, excessive lacrimation, staggering gait, diarrhea,
and cough) were observed, and body temperature was recorded
daily throughout the experiment. Following inoculation,
clinical samples (blood, nasal swabs, and tonsil scrapings)
were collected, and pigs were sacrificed for tissue collection as
follows: group 1, 2 pigs each at 2, 4, 6, 9, and 11 DPI; group 2,
3 pigs each at 2, 4, 6, 9, 11, and 16 DPI; and group 3, 2 pigs at
day 0. Tissue samples (tonsil, mandibular and mesenteric
lymph nodes, spleen, kidney, bone marrow, and brain) were
snap-frozen in liquid nitrogen for virus titration or fixed in 10%
neutral-buffered formalin for histopathological studies.
Remaining animals from groups 1 and 2 were observed for
clinical signs of CSF until day 28.
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randomly allocated into four groups. Pigs in groups 1 and 2
(n = 8) were inoculated with RB-C22v, and animals in groups 3
and 4 (n = 4) were mock-infected. At 7 DPI (groups 1 and 3) or
21 DPI (groups 2 and 4), animals were challenged IN with 105
TCID50 of BICv. Blood, serum, nasal swabs, and tonsil
scrapings were collected at times after challenge. Clinical
signs and body temperature were recorded daily throughout the
experiment.
For early protection studies, pigs (n = 9) were distributed
into three groups of three animals each and inoculated with
RB-C22v. At 1, 3, or 5 DPI, all animals were challenged IN
with 105 TCID50 of BICv. Blood, serum, nasal swabs, and
tonsil scrapings samples were obtained at times after challenge,
and body temperature was recorded daily throughout the
experiment.
To determine viruses (RB-C22v or BICv) present in tissues
in early protection studies, pigs (n = 25) were randomly
distributed in three groups and inoculated IN with 105 TCID50
of RB-C22v (group 1 and 2, n = 10 each) or 105 TCID50 of
BICv (group 3, n = 5). Groups 1 and 2 were challenged IN with
105 TCID50 of BICv at 1 or 3 DPI with RB-C22v, respectively.
Tissue samples (tonsil, mandibular lymph nodes, and spleen)
were obtained (snap-frozen in liquid nitrogen) at 6, 12, 24, 48,
and 72 h post-BICv infection, processed for RNA extraction,
and analyzed by differential PCR.
Clinical samples
Blood, serum, nasal swabs, and tonsil scrapings were
obtained from all animals. Nasal swabs and tonsil scrapings
for virus titration were collected with cotton swabs, placed into
tubes containing 1 ml sterile D-MEM supplemented with
antibiotics, and frozen at 70 -C until used. Peripheral blood
was collected in EDTA tubes and used for virus titration and
hematologic studies. For serological studies, blood was
collected in serum separation tubes. Total white blood cell,
lymphocyte, and platelet counts were obtained using a Beck-
man Coulter AcT (Beckman, Coulter, CA).
Virus titration
Titration of CSFV in clinical samples was performed by
endpoint dilution in 96-well plates (Costar, Cambridge, MA)
using SK6 cells. After 4 days in culture, viral infectivity was
detected by immunoperoxidase assay using the mAB
WH303 and the Vectastain ABC kit (Vector Laboratories,
Burlingames, CA) (Risatti et al., 2003). Titers were
calculated according to the method of Reed and Muench
(1938) and expressed as TCID50/ml. Primary swine macro-
phage cell cultures were prepared as described by Zsak et al.
(1996).
Serology
Serial two-fold dilutions of serum samples in DMEM (10%
v/v FCS, with antibiotics) were added in duplicate to 96-wellplates followed by the addition of an equal volume of D-MEM
containing 200 TCID50 of CSFV strain Brescia. After 1 h of
incubation at 37 -C in a moist chamber, approximately 103
SK6 cells were added per well. Plates were further incubated at
37 -C and 5% CO2 for 4 days. Cell monolayers were then fixed
with methanol:acetone and CSFV detected by immunoperox-
idase staining (see above). Serum neutralization titers were
recorded as the reciprocal of the highest dilution of serum that
inhibited infection of cells.
CSFV-specific antibodies were detected by ELISA using
commercially available kits (HerdChek CSFV Antibody
ELISA, Iddex, Westbrook, ME; and CHEKIT CSF-Sero
ELISA Test, Dr. Bommeli AG, Switzerland) according to
manufacturer’s instructions.
Detection of viral RNA
Clinical and tissue samples obtained from inoculated
animals were analyzed for the presence of viral RNA by
real-time reverse-transcriptase polymerase chain reaction (rt
RT-PCR) targeting a region within the 5V-UTR as previously
described (Risatti et al., 2003).
Differentiation of RB-C22v from BICv by RT-PCR assay
RT-PCR was performed with total RNA extracted from
tissue samples (tonsil, mandibular lymph nodes, and spleen)
using the RNeasy kit (Qiagen Inc., Valencia, CA) according to
manufacturers instructions. A 10 Al RT reaction [1 Al of
MMLV RT buffer, 4 mM dNTPs, 10 pmol of specific reverse
primer R3361 (5VAGCTGTCCCTGGGCTCAT3V), 2 Al of total
RNA, and 5.3 Al of water] was incubated at 70 -C for 5 min,
cooled at room temperature for 20 min, and further incubated
for 1 h at 37 -C following addition of 2 units of MMLV RT
(Stratagene, Cedar Creek, TX). PCR was performed in a 50 Al
reaction [5 Al of 10 Advantage 2 buffer (BD Biosciences
Clontech, Palo Alto, CA), 400 AM of dNTPs, 10 pmol of each
primer F2379 (5VCCTCATCTGCTTGATAAAAG3V) and
R2464 (5VATGATATTGCGTACCTGT3V), 1 Al of Advantage
2 Polymerase Mix (BD Biosciences Clontech) and 2 Al of
cDNA] and included a 95 -C denaturing step for 1 min
followed by 25 cycles at 95 -C for 20 s, 52 -C for 20 s, and
68 -C for 30 s, and a final 68 -C extension cycle for 1 min.
Amplicons of 168 nt for RB-C22v or 111 nt for BICv were
resolved in 2% agarose gels stained with ethidium bromide and
visualized under a UV transilluminator.
Immunohistochemistry (IHC)
Tissue samples were fixed in 10% neutral buffered
formalin, embedded in paraffin, and sectioned. Tissue sections
were allowed to adhere to Superfrost/plus slides (Fisher
Scientific, Pittsburg, PA), heated for 20 min at 65 -C, and
then deparaffinized using xylene. Sections were rehydrated
through a graded alcohol series and washed with phosphate-
buffered saline (PBS) (pH 7.4). Immunohistochemistry (IHC)
was performed as described by Sur et al. (1996). Briefly, 4-
G.R. Risatti et al. / Virology 343 (2005) 116–127126Am sections were first treated with 3% hydrogen peroxide in
PBS for 20 min followed by washes in PBS and digestion
with 0.05% Protease XIV (Sigma Chemical Co., St. Louis,
MO) for 2 min at 37 -C. After several washes with PBS,
sections were incubated in blocking solution (5% normal goat
serum in PBS) for 30 min at room temperature and then
incubated for 2 h at 4 -C with mAB WH303 diluted 1:500 in
PBS. Following additional PBS washes, slides were incubated
with alkaline-phosphatase-conjugated, goat anti-mouse anti-
body for 20 min at room temperature.
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